Sterling Capital Management LLC Sells 3,525 Shares of Biogen Inc. $BIIB

Posted by Brenda Bartman on Jul 1st, 2026

Sterling Capital Management LLC decreased its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 40.7% during the 1st quarter, Holdings Channel reports. The firm owned 5,136 shares of the biotechnology company’s stock after selling 3,525 shares during the period. Sterling Capital Management LLC’s holdings in Biogen were worth $942,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in BIIB. Reflection Asset Management bought a new position in shares of Biogen in the fourth quarter valued at $25,000. WPG Advisers LLC raised its position in Biogen by 417.9% during the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 117 shares in the last quarter. First Horizon Corp acquired a new stake in Biogen in the fourth quarter valued at $30,000. WFA of San Diego LLC acquired a new stake in Biogen in the second quarter valued at $32,000. Finally, Root Financial Partners LLC grew its position in shares of Biogen by 198.4% in the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 123 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Stock Performance

Shares of BIIB stock opened at $216.06 on Wednesday. The company has a market capitalization of $31.90 billion, a price-to-earnings ratio of 23.18 and a beta of 0.20. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. The company has a 50-day simple moving average of $194.96 and a 200 day simple moving average of $186.27. Biogen Inc. has a 52 week low of $121.05 and a 52 week high of $219.72.

Biogen (NASDAQ:BIIB – Get Free Report) last released its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, beating the consensus estimate of $2.95 by $0.62. The firm had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The business’s revenue was up 1.9% on a year-over-year basis. During the same period in the prior year, the firm earned $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, sell-side analysts predict that Biogen Inc. will post 13.95 earnings per share for the current year.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

Positive Sentiment: Needham raised its price target on Biogen to $256 and reiterated a Buy rating, citing stronger-than-expected Spinraza HD momentum and progress across the company’s pipeline. Biogen: Key Takeaways From Needham’s Meeting With Top Management
Positive Sentiment: Biogen said it will showcase new Alzheimer’s disease data at AAIC 2026, including Phase 2 CELIA results for diranersen and additional lecanemab analyses, which could reinforce confidence in one of its key growth areas. Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026
Positive Sentiment: Biogen was highlighted alongside other biotech leaders hitting new 52-week highs, reflecting broader sector strength and momentum in the stock. Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs
Neutral Sentiment: Zacks added Biogen-related ticker BBIB to its Strong Sell list, but this appears to be a separate ticker and not a direct negative on Biogen Inc. itself. New Strong Sell Stocks for June 30th
Negative Sentiment: One report said Biogen is trimming Apellis-related R&D spending and pausing or ending investment in most legacy programs after its acquisition, which may raise integration and capital-allocation concerns. Biogen trims Apellis pipeline and R&D team after $5.6bn takeover
Negative Sentiment: Biogen was also mentioned in a class action settlement notice, which could keep some legal overhang on the shares, though the announcement itself is not a new operational setback. Block & Leviton LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Biogen, Inc. – BIIB

Analyst Ratings Changes

Several research firms have recently weighed in on BIIB. Wedbush boosted their price objective on shares of Biogen from $191.00 to $196.00 and gave the stock a “neutral” rating in a research note on Thursday, April 30th. Needham & Company LLC lifted their price target on Biogen from $255.00 to $256.00 and gave the stock a “buy” rating in a report on Monday. Mizuho lowered their price target on Biogen from $236.00 to $221.00 and set an “outperform” rating on the stock in a research report on Monday, June 15th. Freedom Capital raised Biogen from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 1st. Finally, Citigroup lifted their target price on Biogen from $190.00 to $200.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $217.41.

Read Our Latest Research Report on BIIB

Biogen Company Profile

(Free Report)

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.